Login to Your Account

Financings Roundup

Syndax Secures a Sweet $26.6M Series B

By Marie Powers
Staff Writer

Tuesday, August 27, 2013
Syndax Pharmaceuticals Inc. moved closer to a new drug application (NDA)-enabling Phase III trial of lead candidate entinostat in metastatic breast cancer with a $26.6 million Series B financing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription